Clinical

Dataset Information

0

Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer


ABSTRACT: This study is a retrospective study to compare the efficacy and safety between trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) with TAS-102 monotherapy in refractory metastatic colorectal cancer (mCRC) from November 2020 to October 2022 at the Hunan Cancer Hospital.

DISEASE(S): Metastatic Colorectal Adenocarcinoma,Colorectal Neoplasms

PROVIDER: 60837 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| S-EPMC8658167 | biostudies-literature
| S-EPMC8064512 | biostudies-literature
| 2406756 | ecrin-mdr-crc
2023-09-30 | GSE223927 | GEO
| 2398166 | ecrin-mdr-crc
| 2152626 | ecrin-mdr-crc
| 2653963 | ecrin-mdr-crc
| S-EPMC5717244 | biostudies-literature
2007-08-24 | GSE8849 | GEO
| S-EPMC5635852 | biostudies-literature